These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 22614626)

  • 21. [Chronic kidney disease (CKD) and bone. The mechanisms of chronic kidney disease--mineral and bone disorder (CKD-MBD)].
    Hamada Y; Fukagawa M
    Clin Calcium; 2009 Apr; 19(4):486-92. PubMed ID: 19329826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Kidney and bone update : the 5-year history and future of CKD-MBD. Bone metabolic marker in hemodialysis patients update].
    Okuno S
    Clin Calcium; 2012 Jul; 22(7):1009-17. PubMed ID: 22750933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapy of chronic kidney disease and mineral bone disorder.
    Barreto FC; de Oliveira RA; Oliveira RB; Jorgetti V
    Expert Opin Pharmacother; 2011 Dec; 12(17):2627-40. PubMed ID: 22017388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mineral metabolism and bone abnormalities in children with chronic renal failure.
    Sanchez CP
    Rev Endocr Metab Disord; 2008 Jun; 9(2):131-7. PubMed ID: 18175221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone and mineral disorders after kidney transplantation: therapeutic strategies.
    Molnar MZ; Naser MS; Rhee CM; Kalantar-Zadeh K; Bunnapradist S
    Transplant Rev (Orlando); 2014 Apr; 28(2):56-62. PubMed ID: 24462303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic kidney disease/bone and mineral metabolism: the imperfect storm.
    Williams ME
    Semin Nephrol; 2009 Mar; 29(2):97-104. PubMed ID: 19371800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of bone mineral density in renal transplantation recipients.
    Unal A; Kocyigit I; Sipahioglu MH; Tokgoz B; Kavuncuoglu F; Oymak O; Utas C
    Transplant Proc; 2010 Nov; 42(9):3550-3. PubMed ID: 21094813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients.
    Bozkaya G; Nart A; Uslu A; Onman T; Aykas A; Doğan M; Karaca B
    Transplant Proc; 2008; 40(1):151-5. PubMed ID: 18261573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chronic kidney disease (CKD) and bone. From renal osteodystrophy to CKD-MBD: new disease entity].
    Tsukamoto Y
    Clin Calcium; 2009 Apr; 19(4):479-84. PubMed ID: 19329825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of risedronate on bone in renal transplant recipients.
    Coco M; Pullman J; Cohen HW; Lee S; Shapiro C; Solorzano C; Greenstein S; Glicklich D
    J Am Soc Nephrol; 2012 Aug; 23(8):1426-37. PubMed ID: 22797188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interventions for preventing bone disease in kidney transplant recipients.
    Palmer SC; McGregor DO; Strippoli GF
    Cochrane Database Syst Rev; 2007 Jul; (3):CD005015. PubMed ID: 17636784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving global outcomes in mineral and bone disorders.
    Moe SM; Drüeke T
    Clin J Am Soc Nephrol; 2008 Nov; 3 Suppl 3(Suppl 3):S127-30. PubMed ID: 18988697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials.
    Wang J; Yao M; Xu JH; Shu B; Wang YJ; Cui XJ
    Osteoporos Int; 2016 May; 27(5):1683-90. PubMed ID: 26733377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Kidney transplantation: prevention and treatment for bone loss after transplantation].
    Kokado Y
    Clin Calcium; 2006 Jan; 16(1):86-91. PubMed ID: 16397356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Markers of calcium--phosphate metabolism and bones alterations in long term kidney transplant patients].
    Spiechowicz U; Kokot F; Wiecek A
    Przegl Lek; 2003; 60(11):690-4. PubMed ID: 15058034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
    Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
    J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of alendronate sodium (Fosamax) to ameliorate osteoporosis in renal transplant patients: a case-control study.
    Huang WH; Lee SY; Weng CH; Lai PC
    PLoS One; 2012; 7(11):e48481. PubMed ID: 23185261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteoporosis after organ transplantation.
    Rodino MA; Shane E
    Am J Med; 1998 May; 104(5):459-69. PubMed ID: 9626030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone Mineral Density and Bone Turnover Markers Under Bisphosphonate Therapy Used in the First Year After Liver Transplantation.
    Nowacka-Cieciura E; Sadowska A; Pacholczyk M; Chmura A; Tronina O; Durlik M
    Ann Transplant; 2016 Apr; 21():241-9. PubMed ID: 27112626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.
    Pimentel A; Ureña-Torres P; Zillikens MC; Bover J; Cohen-Solal M
    Kidney Int; 2017 Dec; 92(6):1343-1355. PubMed ID: 28964571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.